[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA31949B1 - Dérivés d'aminotriazole comme agonistes d'alx - Google Patents

Dérivés d'aminotriazole comme agonistes d'alx

Info

Publication number
MA31949B1
MA31949B1 MA32968A MA32968A MA31949B1 MA 31949 B1 MA31949 B1 MA 31949B1 MA 32968 A MA32968 A MA 32968A MA 32968 A MA32968 A MA 32968A MA 31949 B1 MA31949 B1 MA 31949B1
Authority
MA
Morocco
Prior art keywords
alx
antagonist
aminotriazole derivatives
derivatives act
aminotriazole
Prior art date
Application number
MA32968A
Other languages
Arabic (ar)
English (en)
Inventor
Daniel Bur
Sylvaine Cren
Olivier Corminboeuf
Corinna Grisostomi
Xavier Leroy
Sylvia Richard-Bildstein
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA31949B1 publication Critical patent/MA31949B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des dérivés d'aminotriazole de la formule (i), dans laquelle a, e, r1 et r2 sont tels que définis dans la description, ainsi que leur préparation et leur utilisation comme composés pharmaceutiquement actifs. Les composés sont utiles pour la prévention ou le traitement de maladies qui répondent à la modulation du récepteur alx telles que des maladies inflammatoires.
MA32968A 2007-12-18 2010-06-29 Dérivés d'aminotriazole comme agonistes d'alx MA31949B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2007055199 2007-12-18
IB2008054369 2008-10-23
PCT/IB2008/055375 WO2009077990A1 (fr) 2007-12-18 2008-12-17 Dérivés d'aminotriazole comme agonistes d'alx

Publications (1)

Publication Number Publication Date
MA31949B1 true MA31949B1 (fr) 2010-12-01

Family

ID=40404773

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32968A MA31949B1 (fr) 2007-12-18 2010-06-29 Dérivés d'aminotriazole comme agonistes d'alx

Country Status (26)

Country Link
US (1) US8536209B2 (fr)
EP (1) EP2225231B1 (fr)
JP (1) JP4656674B2 (fr)
KR (1) KR101213007B1 (fr)
CN (1) CN101903378B (fr)
AR (1) AR069801A1 (fr)
AT (1) ATE520689T1 (fr)
AU (1) AU2008337097B2 (fr)
BR (1) BRPI0821115A8 (fr)
CA (1) CA2706839C (fr)
CY (1) CY1112465T1 (fr)
DK (1) DK2225231T3 (fr)
HK (1) HK1144158A1 (fr)
HR (1) HRP20110825T1 (fr)
IL (1) IL206399A (fr)
MA (1) MA31949B1 (fr)
MX (1) MX2010006241A (fr)
MY (1) MY153985A (fr)
NZ (1) NZ586735A (fr)
PL (1) PL2225231T3 (fr)
PT (1) PT2225231E (fr)
RU (1) RU2492167C2 (fr)
SI (1) SI2225231T1 (fr)
TW (1) TWI434685B (fr)
WO (1) WO2009077990A1 (fr)
ZA (1) ZA201005080B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
MX2011012264A (es) 2009-05-18 2011-12-12 Actelion Pharmaceuticals Ltd Derivados spiro[2.4]heptano puenteados como agonistas del receptor de lipoxina a(alx) y/o de formil peptido tipo 2 (fprl2).
ES2587139T3 (es) * 2009-06-09 2016-10-20 Actelion Pharmaceuticals Ltd. Derivados fluorados de aminotriazol
CN102803237B (zh) * 2009-06-12 2014-09-24 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑和噻唑衍生物
EP2640699B1 (fr) 2010-11-17 2015-10-07 Actelion Pharmaceuticals Ltd. Dérivés d'esters de spiro[2.4]heptane pontés
AU2011340146B2 (en) 2010-12-07 2016-05-19 Idorsia Pharmaceuticals Ltd Oxazolyl-methylether derivatives as ALX receptor agonists
RU2013130878A (ru) * 2010-12-07 2015-01-20 Актелион Фармасьютиклз Лтд Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx
US20140113824A1 (en) 2011-05-10 2014-04-24 Bayer Intellectual Property Gmbh Bicyclic (thio)carbonylamidines
WO2013022766A1 (fr) * 2011-08-05 2013-02-14 Flynn Gary A Préparation et procédés d'utilisation d'ortho-aryle hétéroaryle à 5 chaînons -carboxamide contenant des inhibiteurs de kinases multicibles
CN102558117B (zh) * 2011-12-15 2014-10-08 北京金骄生物质化工有限公司 一种利用废弃生物质制备5-硝基-2-糠酸酯的方法
ES2596521T3 (es) 2012-05-16 2017-01-10 Actelion Pharmaceuticals Ltd. Derivados de espiro[2.4]heptano sustituidos con puente 1-(p-tolil)ciclopropilo como agonistas de receptor de ALX
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
NZ703448A (en) 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
WO2014057435A1 (fr) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Antagonistes des récepteurs de l'orexine, qui sont des dérivés [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone
MX2015006716A (es) * 2012-12-03 2015-08-14 Hoffmann La Roche Compuestos de triazol e imidazol sustituidos.
KR20150130413A (ko) 2013-03-12 2015-11-23 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서의 아제티딘 아미드 유도체
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
ES2639798T3 (es) 2013-07-18 2017-10-30 Idorsia Pharmaceuticals Ltd Derivados de espiro[2.4]heptano con puente sustituidos con piperazina como agonistas del receptor ALX
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
CA2932010C (fr) 2013-11-28 2020-07-07 Kyorin Pharmaceutical Co., Ltd. Derive d'uree ou sel pharmacologiquement acceptable de celui-ci
UA116053C2 (uk) 2013-12-04 2018-01-25 Ідорсія Фармасьютікалз Лтд Застосування похідних бензоімідазолу-проліну
CN107849049B (zh) 2015-05-27 2021-03-16 杏林制药株式会社 脲衍生物或其药用盐
ES2791340T3 (es) 2015-05-27 2020-11-03 Kyorin Seiyaku Kk Derivado de urea o sal farmacológicamente aceptable del mismo
US20180325869A1 (en) * 2015-11-24 2018-11-15 Bristol-Myers Squibb Company Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
EP3762380B1 (fr) 2018-03-05 2021-12-15 Bristol-Myers Squibb Company Agonistes du récepteur 2 du peptide formylé de phénylpyrrolidinone
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
AU2002359311A1 (en) 2001-10-26 2003-05-06 Government Of The United States Of America, As Represented By The Secretary, Department Of Health An Amyloid ss is a ligand for fpr class receptors
EP1492552A2 (fr) 2002-04-03 2005-01-05 Bayer Aktiengesellschaft Diagnostics et therapies pour maladies liees a un recepteur de type 1 de peptides n-formyl (fprl1)
EP1692502A2 (fr) * 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Utilisation d'un recepteur de lipoxine, fprl1, en tant qu'outil d'identification de composes efficaces dans le traitement de douleurs et d'inflammations
WO2005115383A2 (fr) * 2004-05-25 2005-12-08 Metabolex, Inc. Triazoles substitués comme modulateurs de ppar et méthodes de préparation
WO2006063585A1 (fr) * 2004-12-13 2006-06-22 Leo Pharma A/S Dérivés d'aminobenzophénone substitués par un triazole
WO2007055941A2 (fr) * 2005-11-03 2007-05-18 Merck & Co., Inc. Inhibiteurs de l'histone desacetylase a motifs d'aryle-pyrazolyle
WO2007125405A2 (fr) * 2006-05-01 2007-11-08 Pfizer Products Inc. Composés hétérocycliques 2-amino-substitués à cycles fusionnés
WO2009025793A2 (fr) 2007-08-21 2009-02-26 Senomyx, Inc. Identification de récepteurs humains t2r sensibles aux composés amers qui provoquent le goût amer dans des compositions, et utilisation de ceux-ci dans des analyses d'identification de composés qui inhibent (bloquent) le goût amer dans des compositions et utilisation de celles-ci
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
MX2011012264A (es) 2009-05-18 2011-12-12 Actelion Pharmaceuticals Ltd Derivados spiro[2.4]heptano puenteados como agonistas del receptor de lipoxina a(alx) y/o de formil peptido tipo 2 (fprl2).
ES2587139T3 (es) 2009-06-09 2016-10-20 Actelion Pharmaceuticals Ltd. Derivados fluorados de aminotriazol
CN102803237B (zh) 2009-06-12 2014-09-24 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑和噻唑衍生物

Also Published As

Publication number Publication date
CN101903378A (zh) 2010-12-01
EP2225231A1 (fr) 2010-09-08
AR069801A1 (es) 2010-02-17
NZ586735A (en) 2012-06-29
BRPI0821115A2 (pt) 2015-06-16
IL206399A0 (en) 2010-12-30
EP2225231B1 (fr) 2011-08-17
BRPI0821115A8 (pt) 2017-12-26
JP2011506594A (ja) 2011-03-03
WO2009077990A1 (fr) 2009-06-25
AU2008337097B2 (en) 2014-03-20
DK2225231T3 (da) 2011-10-17
HRP20110825T1 (hr) 2011-12-31
US8536209B2 (en) 2013-09-17
CA2706839A1 (fr) 2009-06-25
SI2225231T1 (sl) 2011-12-30
TW200932216A (en) 2009-08-01
HK1144158A1 (en) 2011-01-28
PL2225231T3 (pl) 2012-01-31
CN101903378B (zh) 2014-03-12
CA2706839C (fr) 2015-10-20
RU2492167C2 (ru) 2013-09-10
AU2008337097A1 (en) 2009-06-25
CY1112465T1 (el) 2015-12-09
MY153985A (en) 2015-04-30
TWI434685B (zh) 2014-04-21
KR101213007B1 (ko) 2012-12-20
PT2225231E (pt) 2011-10-19
MX2010006241A (es) 2010-06-30
ATE520689T1 (de) 2011-09-15
JP4656674B2 (ja) 2011-03-23
IL206399A (en) 2016-03-31
ZA201005080B (en) 2011-12-28
US20100331378A1 (en) 2010-12-30
KR20100092516A (ko) 2010-08-20
RU2010129272A (ru) 2012-01-27

Similar Documents

Publication Publication Date Title
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA33365B1 (fr) Dérivés de spiro[2.4]heptane pontés utiles en tant qu'agonistes du récepteur de alx et/ou du récepteur fprl2
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA31766B1 (fr) Composés organiques
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA28269A1 (fr) Arylpyrazoles substitués servant d'agents parasiticides
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA27728A1 (fr) Antagonistes des recepteurs de cgrp
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
TNSN05298A1 (fr) Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs